CN108135737B - 用于治疗翼状胬肉的组合物和方法 - Google Patents

用于治疗翼状胬肉的组合物和方法 Download PDF

Info

Publication number
CN108135737B
CN108135737B CN201680042858.1A CN201680042858A CN108135737B CN 108135737 B CN108135737 B CN 108135737B CN 201680042858 A CN201680042858 A CN 201680042858A CN 108135737 B CN108135737 B CN 108135737B
Authority
CN
China
Prior art keywords
pterygium
formulation
sustained release
nintedanib
multikinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680042858.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108135737A (zh
Inventor
J.倪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pokvision Cloud Biomedical Technology Guangzhou Co ltd
Original Assignee
Poyun Biomedical Technology Guangzhou Co ltd
Cloudbreak Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57504837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108135737(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Poyun Biomedical Technology Guangzhou Co ltd, Cloudbreak Therapeutics LLC filed Critical Poyun Biomedical Technology Guangzhou Co ltd
Priority to CN202111180633.1A priority Critical patent/CN114010787A/zh
Publication of CN108135737A publication Critical patent/CN108135737A/zh
Application granted granted Critical
Publication of CN108135737B publication Critical patent/CN108135737B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201680042858.1A 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法 Active CN108135737B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111180633.1A CN114010787A (zh) 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562172063P 2015-06-06 2015-06-06
US62/172,063 2015-06-06
US201562186660P 2015-06-30 2015-06-30
US62/186,660 2015-06-30
PCT/US2016/035726 WO2016200688A1 (en) 2015-06-06 2016-06-03 Compositions and methods for treating pterygium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111180633.1A Division CN114010787A (zh) 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法

Publications (2)

Publication Number Publication Date
CN108135737A CN108135737A (zh) 2018-06-08
CN108135737B true CN108135737B (zh) 2021-11-05

Family

ID=57504837

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680042858.1A Active CN108135737B (zh) 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法
CN202111180633.1A Pending CN114010787A (zh) 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111180633.1A Pending CN114010787A (zh) 2015-06-06 2016-06-03 用于治疗翼状胬肉的组合物和方法

Country Status (10)

Country Link
US (7) US9980901B2 (cg-RX-API-DMAC10.html)
EP (2) EP4335418A3 (cg-RX-API-DMAC10.html)
JP (6) JP6868014B2 (cg-RX-API-DMAC10.html)
KR (5) KR102643821B1 (cg-RX-API-DMAC10.html)
CN (2) CN108135737B (cg-RX-API-DMAC10.html)
AU (4) AU2016276170B2 (cg-RX-API-DMAC10.html)
ES (1) ES2971096T3 (cg-RX-API-DMAC10.html)
MX (2) MX393691B (cg-RX-API-DMAC10.html)
TW (1) TWI714596B (cg-RX-API-DMAC10.html)
WO (1) WO2016200688A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
TWI664965B (zh) * 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10335313B2 (en) * 2017-08-16 2019-07-02 Brian S. Boxer Wachler Method for removing colored spots to whiten the eye
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
US20190346048A1 (en) 2018-05-11 2019-11-14 Quarter Turn Pressure Control, LLC Replaceable body saver
KR20210013574A (ko) * 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법
US10941902B2 (en) 2018-07-10 2021-03-09 Quarter Turn Pressure Control, LLC Valve grease blocks for high pressure valves and high pressure valves using the same
JP2021534153A (ja) * 2018-08-15 2021-12-09 アイビバ バイオファーマ インコーポレイテッド Ｖｅｇｆおよびｔｇｆベータのマルチキナーゼ阻害剤およびその使用
US20210315815A1 (en) * 2018-08-28 2021-10-14 Cloudbreak Therapeutics, Llc Emulsion formulations of multikinase inhibitors
US10744153B1 (en) * 2019-07-01 2020-08-18 Cloudbreak Therapeutics Llc Compositions and methods for treating meibomian gland dysfunction
BR112021026662A2 (pt) * 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
CA3168400A1 (en) * 2020-02-19 2021-08-26 Vestlandets Innovasjonsselskap As Treatment of corneal vascularisation
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
AU2021282983B2 (en) * 2020-06-01 2026-06-11 Ads Therapeutics Llc Topical ophthalmological compositions and methods for treating abnormal angiogenesis
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
CN113425728A (zh) * 2021-06-29 2021-09-24 复旦大学附属眼耳鼻喉科医院 一种zd6474在翼状胬肉术后抗复发的治疗药物制备中的应用
JP2025525881A (ja) * 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤
AU2022488910A1 (en) * 2022-12-13 2025-06-19 Suzhou Raymon Pharmaceuticals Company, Ltd. Use of naphthylurea compounds in preparation of drugs for treating pterygium
JP2026520094A (ja) 2023-04-11 2026-06-22 オキュラ セラピューティクス，インコーポレイテッド アキシチニブ多形ｉｖを含む眼科インプラント
USD1122994S1 (en) * 2023-11-30 2026-04-21 J. C. Bamford Excavators Limited Part of an excavator arm

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1247469A (zh) * 1997-02-14 2000-03-15 橘生药品工业株式会社 抑制翼状胬肉发展及其术后复发的药物
CN100455568C (zh) * 1999-10-13 2009-01-28 贝林格尔英格海姆法玛两合公司 6-位取代的吲哚满酮,其制备及其作为药物组合物的用途
RU2351298C1 (ru) * 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ профилактики рецидива птеригиума
CN102018686A (zh) * 2010-12-16 2011-04-20 浙江大学医学院附属邵逸夫医院 含有丝裂霉素的膜剂及其制备方法
CN103212075A (zh) * 2012-01-19 2013-07-24 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
CN103764118A (zh) * 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
CN103889399A (zh) * 2011-06-28 2014-06-25 拜尔健康护理有限责任公司 含有瑞格非尼的局部眼用药物组合物
CN103998431A (zh) * 2011-10-20 2014-08-20 阿勒根公司 作为酪氨酸激酶抑制剂的吡啶-亚砜亚胺
CN104379128A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有西地尼布的局部眼科药物组合物
CN104379133A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有阿昔替尼的局部眼科药物组合物
CN104379129A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有帕唑帕尼的局部眼科药物组合物
CN104448300A (zh) * 2014-12-09 2015-03-25 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
CN104582685A (zh) * 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006020979A2 (en) * 2004-08-13 2006-02-23 Yale University Factor vii conjugates for selectively treating neovascularization disorders
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20080003219A1 (en) * 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
PL2299987T3 (pl) 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
US20100185564A1 (en) 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
KR102337046B1 (ko) * 2010-01-22 2021-12-08 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
EP3181128B1 (en) 2012-01-13 2023-03-08 XSpray Pharma AB (publ) Nilotinib pharmaceuticalcomposition
HK1205461A1 (zh) 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
WO2014059233A1 (en) 2012-10-11 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Ocular filtration devices, systems and methods
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
EP2919802A4 (en) 2012-11-15 2016-09-14 Univ Tufts METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
WO2014158863A1 (en) * 2013-03-14 2014-10-02 Massachusetts Eye And Ear Infirmary Conjunctival diseases
WO2014165308A2 (en) * 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
SG10201702674PA (en) * 2013-05-03 2017-06-29 Clearside Biomedical Inc Apparatus and methods for ocular injection
US20140378401A1 (en) 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US10010610B2 (en) 2014-01-16 2018-07-03 Retinal Therapies, LLC Compositions and methods for the treatment of intraocular neovascularization and/or leakage
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
AU2016211630B2 (en) 2015-01-26 2021-03-25 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
EA035465B1 (ru) 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
TWI664965B (zh) 2015-06-22 2019-07-11 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
JP2018525078A (ja) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 被覆された涙点プラグ
MX394623B (es) 2016-02-04 2025-03-24 Ads Therapeutics Llc Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades.
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
JP7018939B2 (ja) 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
JP7306697B2 (ja) 2017-03-14 2023-07-11 オールジェネシス バイオセラピューティクス インコーポレイテッド ３－ｚ－［１－（４－（ｎ－（（４－メチル－ピペラジン－１－イル）－メチルカルボニル）－ｎ－メチル－アミノ）－フェニルアミノ）－１－フェニル－メチレン］－６－メトキシカルボニル－２－インドリノンの結晶形
KR20210013574A (ko) 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법
CN110664757B (zh) 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
BR112021026662A2 (pt) 2019-09-10 2022-04-12 Cloudbreak Therapeutics Llc Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho
CN119745879A (zh) 2020-02-19 2025-04-04 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
CN116251186B (zh) 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1247469A (zh) * 1997-02-14 2000-03-15 橘生药品工业株式会社 抑制翼状胬肉发展及其术后复发的药物
CN100455568C (zh) * 1999-10-13 2009-01-28 贝林格尔英格海姆法玛两合公司 6-位取代的吲哚满酮,其制备及其作为药物组合物的用途
RU2351298C1 (ru) * 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ профилактики рецидива птеригиума
CN102018686A (zh) * 2010-12-16 2011-04-20 浙江大学医学院附属邵逸夫医院 含有丝裂霉素的膜剂及其制备方法
CN103889399A (zh) * 2011-06-28 2014-06-25 拜尔健康护理有限责任公司 含有瑞格非尼的局部眼用药物组合物
CN103764118A (zh) * 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
CN103998431A (zh) * 2011-10-20 2014-08-20 阿勒根公司 作为酪氨酸激酶抑制剂的吡啶-亚砜亚胺
CN103212075A (zh) * 2012-01-19 2013-07-24 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
CN104379128A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有西地尼布的局部眼科药物组合物
CN104379133A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有阿昔替尼的局部眼科药物组合物
CN104379129A (zh) * 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有帕唑帕尼的局部眼科药物组合物
CN104582685A (zh) * 2012-06-25 2015-04-29 拜尔健康护理有限责任公司 含有舒尼替尼的局部眼科药物组合物
CN104448300A (zh) * 2014-12-09 2015-03-25 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Correlation of Vascular Endothelial Growth Factor and CD105-Microvascular Densisy in Primary Pterygium;Jie ZHANG;《J Huazhong Univ Sci Technol》;20111231;全文 *
Growth factors in cultured pterygium fibroblasts:immunohistochemical and ELISA analysis;Lidia Kria;《Graefe"s Arch Clin Exp Ophthalmol》;19981231;全文 *
Horizons in Therapy for Corneal Angiogenesis;Surekha Maddula;《Ophthalmology》;20150228;全文 *
Immunohistochemical localization of basic fibroblast growth factor,platelet derived growth factor, transforming growth factor-p and tumor necrosis factor-a in the pterygium;Lidia Kria;《Acta histochem》;19961231;全文 *
Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye;Viet Anh Nguyen Huu;《Journal of Controlled Release》;20150228;全文 *
Safety and Efficacy of the Multitargeted Receptor Kinase Inhibitor Pazopanib in the Treatment of Corneal Neovascularization;Francisco Amparo;《Investigative Ophthalmology & Visual Science》;20130131;全文 *
The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium;Kareem;《Clinical Ophthalmology》;20121101;第2012卷(第6期);摘要以及表2 *
Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium;MeiLing Peng;《Br J Ophthalmol》;20131011;全文 *

Also Published As

Publication number Publication date
JP2018521120A (ja) 2018-08-02
AU2021218212A1 (en) 2021-09-09
KR20240043821A (ko) 2024-04-03
US9987223B2 (en) 2018-06-05
EP4335418A3 (en) 2024-05-22
JP6868014B2 (ja) 2021-05-12
TW201709910A (zh) 2017-03-16
EP3302379A4 (en) 2019-01-23
US9980901B2 (en) 2018-05-29
US10149819B2 (en) 2018-12-11
US20180271781A1 (en) 2018-09-27
US20170209368A1 (en) 2017-07-27
AU2021218212B2 (en) 2023-11-16
WO2016200688A1 (en) 2016-12-15
KR20180030499A (ko) 2018-03-23
KR102906248B1 (ko) 2026-01-02
JP2021113201A (ja) 2021-08-05
MX393691B (es) 2025-03-24
JP2025094111A (ja) 2025-06-24
MX2017015838A (es) 2018-08-15
KR20240034866A (ko) 2024-03-14
KR20260046518A (ko) 2026-04-07
CN114010787A (zh) 2022-02-08
JP7868283B1 (ja) 2026-06-01
US20170172915A1 (en) 2017-06-22
US20250262148A1 (en) 2025-08-21
AU2024200946B2 (en) 2026-03-26
EP3302379A1 (en) 2018-04-11
US20210308042A1 (en) 2021-10-07
KR102643821B1 (ko) 2024-03-07
KR20260025887A (ko) 2026-02-24
HK1253895A1 (en) 2019-07-05
US12186424B2 (en) 2025-01-07
BR112017025122A2 (pt) 2018-07-31
CA2988293A1 (en) 2016-12-15
EP4335418A2 (en) 2024-03-13
JP7774170B2 (ja) 2025-11-20
ES2971096T3 (es) 2024-06-03
JP2024069363A (ja) 2024-05-21
JP2026102822A (ja) 2026-06-23
MX2022007989A (es) 2022-07-21
HK1256602A1 (zh) 2019-09-27
US10149820B2 (en) 2018-12-11
JP7234283B2 (ja) 2023-03-07
CN108135737A (zh) 2018-06-08
JP7571171B2 (ja) 2024-10-22
AU2024200946A1 (en) 2024-02-29
JP7838007B2 (ja) 2026-03-31
TWI714596B (zh) 2021-01-01
US10980741B2 (en) 2021-04-20
AU2016276170A1 (en) 2017-12-14
AU2026204560A1 (en) 2026-07-02
JP2023062133A (ja) 2023-05-02
US20180271780A1 (en) 2018-09-27
AU2016276170B2 (en) 2021-08-05
EP3302379B1 (en) 2023-11-22
US20190110984A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
JP7774170B2 (ja) 翼状片を治療するための組成物及び方法
HK40069641A (en) Compositions and methods for treating pterygium
HK1256602B (en) Compositions and methods for treating pterygium
CA2988293C (en) Compositions and methods for treating pterygium
HK40101374A (en) Compositions and methods for treating pterygium
BR112017025122B1 (pt) Uso de nintedanib para tratar pterígio
HK1253895B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181225

Address after: Unit 214-43, Second Floor, No. 1 Spiral Fourth Road, International Biological Island, Huangpu District, Guangzhou City, Guangdong Province

Applicant after: Poyun biomedical technology (Guangzhou) Co.,Ltd.

Address before: California, USA

Applicant before: CLOUDBREAK THERAPEUTICS LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256602

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 510663 room 327, building G1, No. 31 Kefeng Road, Huangpu District, Guangzhou, Guangdong

Patentee after: Pokvision Cloud Biomedical Technology (Guangzhou) Co.,Ltd.

Country or region after: China

Address before: 510300 unit 214-43, second floor, office area, No. 1, helix 4th Road, International Biological Island, Huangpu District, Guangzhou, Guangdong Province

Patentee before: Poyun biomedical technology (Guangzhou) Co.,Ltd.

Country or region before: China